Much of Pfizer's revenue is driven by therapies with only modest competition. This stock is also developing a very impressive dividend-growth track record.
Despite a tanking stock price, Pfizer has raised its dividend for 15 consecutive years. Pfizer's profits are off their peak but more than sufficient to continue raising the dividend.
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
Pharmaceutical giant Pfizer Inc. NYSE: PFE has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound makers Eli Lilly & Co. NYSE: LLY. Pfizer had failed in its previous attempts to create a viable GLP-1 contender.
Pfizer is in the midst of transition as it faces multiple patent cliffs. The company's growth strategy suggests that the business could be bigger by the end of the decade, but not necessarily by a whole lot.
London's High Court on Tuesday ruled that one of Moderna's patents relating to technology key to the development of vaccines for COVID-19 was invalid, but that another was valid and had been infringed by Pfizer and BioNTech's rival vaccine.
When excluding sales Pfizer generated due to COVID-19 vaccines and medication, the business is reporting solid growth. Especially the oncology business will drive growth in the years to come, and the Seagan acquisition might also contribute. With its high dividend yield and rather undervalued stock, PFE stock is a "Buy" at this point.
There is no evidence of major birth defects in babies born to mothers vaccinated against COVID-19 during the first trimester of pregnancy, according to new research published in JAMA Pediatrics on Monday, underscoring the safety of vaccination during pregnancy amid mounting evidence of the severe health risks infections can cause for mothers and babies.
Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.
Pfizer appears to be on its way toward stabilizing its business and winning back Wall Street's favor after the sudden decline of its Covid business. But the company is struggling to balance that with the concerns and fears of its workers.
Pfizer shares have suffered a painful slide as pandemic revenue dried up. But management is committed to maintaining and growing the dividend.
A rare-disease drugmaker and a top pharmaceutical stock have what it takes to deliver solid returns over the long run. Vertex Pharmaceuticals' flagship business continues to expand market share and profits.